Myomo, Inc. (MYO)
USD 4.8
(3.12%)
USD 4.8
(3.12%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.23 Million USD | 22.87% |
| 2022 | -10.67 Million USD | -3.94% |
| 2021 | -10.26 Million USD | 2.23% |
| 2020 | -10.5 Million USD | 2.71% |
| 2019 | -10.79 Million USD | -2.53% |
| 2018 | -10.52 Million USD | -60.79% |
| 2017 | -6.54 Million USD | -99.94% |
| 2016 | -3.27 Million USD | 7.32% |
| 2015 | -3.53 Million USD | -28.9% |
| 2014 | -2.74 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -3.88 Million USD | -59.82% |
| 2024 Q2 | -1.11 Million USD | 71.33% |
| 2023 FY | -8.23 Million USD | 22.87% |
| 2023 Q3 | -2.02 Million USD | -83.53% |
| 2023 Q1 | -2.67 Million USD | -19.81% |
| 2023 Q4 | -2.43 Million USD | -20.19% |
| 2023 Q2 | -1.1 Million USD | 58.7% |
| 2022 Q2 | -2.88 Million USD | -5.42% |
| 2022 Q1 | -2.73 Million USD | -1.19% |
| 2022 FY | -10.67 Million USD | -3.94% |
| 2022 Q4 | -2.22 Million USD | 20.91% |
| 2022 Q3 | -2.81 Million USD | 2.34% |
| 2021 Q4 | -2.7 Million USD | -33.27% |
| 2021 Q2 | -2.59 Million USD | 11.35% |
| 2021 Q1 | -2.93 Million USD | -73.87% |
| 2021 FY | -10.26 Million USD | 2.23% |
| 2021 Q3 | -2.03 Million USD | 21.9% |
| 2020 FY | -10.5 Million USD | 2.71% |
| 2020 Q2 | -2.84 Million USD | 16.77% |
| 2020 Q3 | -2.54 Million USD | 10.65% |
| 2020 Q4 | -1.68 Million USD | 33.73% |
| 2020 Q1 | -3.42 Million USD | -32.61% |
| 2019 Q4 | -2.58 Million USD | 8.65% |
| 2019 FY | -10.79 Million USD | -2.53% |
| 2019 Q3 | -2.82 Million USD | -4.39% |
| 2019 Q2 | -2.7 Million USD | -0.88% |
| 2019 Q1 | -2.68 Million USD | 1.91% |
| 2018 Q1 | -2.4 Million USD | -32.32% |
| 2018 Q4 | -2.73 Million USD | -0.98% |
| 2018 FY | -10.52 Million USD | -60.79% |
| 2018 Q2 | -2.68 Million USD | -11.62% |
| 2018 Q3 | -2.7 Million USD | -0.98% |
| 2017 Q2 | -1.93 Million USD | -41.78% |
| 2017 Q1 | -1.36 Million USD | -24.31% |
| 2017 Q3 | -1.43 Million USD | 25.78% |
| 2017 Q4 | -1.81 Million USD | -26.55% |
| 2017 FY | -6.54 Million USD | -99.94% |
| 2016 Q4 | -1.09 Million USD | -17.47% |
| 2016 Q2 | -688.57 Thousand USD | -23.38% |
| 2016 Q3 | -933.82 Thousand USD | -35.62% |
| 2016 Q1 | -558.11 Thousand USD | 34.27% |
| 2016 FY | -3.27 Million USD | 7.32% |
| 2015 FY | -3.53 Million USD | -28.9% |
| 2015 Q1 | -917.63 Thousand USD | 0.0% |
| 2015 Q4 | -849.11 Thousand USD | 0.0% |
| 2015 Q3 | -849.11 Thousand USD | 7.47% |
| 2015 Q2 | -917.63 Thousand USD | 0.0% |
| 2014 FY | -2.74 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 100.127% |
| Allurion Technologies Inc. | -78.07 Million USD | 89.457% |
| Artivion, Inc. | 5.74 Million USD | 243.357% |
| Avanos Medical, Inc. | 4.2 Million USD | 295.989% |
| Butterfly Network, Inc. | -145.61 Million USD | 94.347% |
| Butterfly Network, Inc. | -145.61 Million USD | 94.347% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 102.145% |
| Boston Scientific Corporation | 2.34 Billion USD | 100.351% |
| CONMED Corporation | 130.78 Million USD | 106.294% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 100.537% |
| Paragon 28, Inc. | -37.3 Million USD | 77.937% |
| Glaukos Corporation | -128.7 Million USD | 93.604% |
| Globus Medical, Inc. | 133.14 Million USD | 106.183% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | 79.56% |
| Integer Holdings Corporation | 167.33 Million USD | 104.919% |
| Medtronic plc | 5.14 Billion USD | 100.16% |
| Nevro Corp. | -99.3 Million USD | 91.711% |
| Owlet, Inc. | -28.63 Million USD | 71.251% |
| Penumbra, Inc. | 73.55 Million USD | 111.192% |
| Vicarious Surgical Inc. | -80.66 Million USD | 89.796% |
| Smith & Nephew plc | 425 Million USD | 101.937% |
| Sonendo, Inc. | -57.74 Million USD | 85.745% |
| STERIS plc | 836.11 Million USD | 100.984% |
| Stryker Corporation | 3.88 Billion USD | 100.212% |
| Vapotherm, Inc. | -39.08 Million USD | 78.937% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 100.644% |